CrossLend Structures an Investment Grade Rated ESG Note for Bikeleasing and MEAG as a Digital Asset
Berlin-based FinTech CrossLend has issued a note to facilitate an investment into lease contracts for bicycles. The transaction is the result of a collaboration between Bikeleasing - the fastest growing e-bike leasing provider, MEAG as asset manager, ERGO as investor, and CrossLend as the structurer and operator of the digital register. Scope rated the note as investment grade and confirmed the ecological impact of the issued note is in accordance with the ICMA Green Bond Principles as part of a second party opinion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211012005499/en/
Marco Hinz (Chief Operating Officer) and Oliver Schimek (Chief Executive Officer & Founder), CrossLend GmbH (Photo: Business Wire)
The transaction reflects several market trends. The goals of a climate-neutral society require substantial investments to replace goods such as cars or heating devices which, in their normal lifespan, would still have years of operation ahead of them. At the same time, cost-intensive innovative products are being offered as part of convenient pay-as-you-go models which contain a lending product and require refinancing. As a result, highly innovative originators such as Bikeleasing are entering into an origination model in competition with banks, or even closing gaps where traditional banking products are not covering the needs of customers. The kinetics in terms of origination frequency, and the level of fragmentation seen in the single tickets of such originations, require a digital and data-driven transactional link to traditional capital market investors. Accordingly, CrossLend structured and issued a note on its digital asset register which complied with the ICMA Green Bond Principles.
"The transformation of the economy and society towards climate-friendly technologies requires unparalleled investments in a relatively short period of time. The reality is that non-digital investment banking cannot keep up with the kinetics of innovative product providers such as Bikeleasing. We are extremely proud that our digital asset technology closes a gap between agile, transformative products and the capital markets, enabling established institutions like MEAG and ERGO to conveniently invest to support ecological change," says Oliver Schimek, Chief Executive Officer of CrossLend GmbH.
According to Thomas Bayerl, Head of Illiquid Assets Debt at MEAG: "As an asset manager, we work in an environment where digital transformation and sustainability criteria play an increasing role in the development of investable assets. CrossLend's digital asset platform and register were instrumental in making this asset accessible for our client ERGO today. This transaction can serve as a successful example for further implementation possibilities in a variety of industries."
Paul Sinizin, co-founder and CEO of Bikeleasing comments: "Bikeleasing has been growing extremely fast and we still see a large untapped market opportunity ahead. For our growth we require a flexible and scalable funding source. Working with a technology platform like CrossLend allows us to minimise our operational efforts on the capital markets activity through automation and industrialisation."
About CrossLend
CrossLend is a FinTech company that provides full spectrum technology for loan asset transactions. Its mission is to make the world's lending and investment ecosystem more efficient, transparent, and profitable. Supervised by BaFIN and CSSF, CrossLend is backed by an array of prestigious equity investors from Europe and the US, including Mouro Capital (formerly Santander InnoVentures), Lakestar, CME Ventures, Earlybird, ABN AMRO's Digital Impact Fund, and the Luxembourg Future Fund (EIF and SNCI).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005499/en/
Contact information
Media officer
Agnieszka Szczesna
Tel: +49 30 208 488 133
media@crosslend.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
